Explore ViiV Healthcare

I am a ▾
  • HCP
  • person living with HIV
  • NGO or patient group
  • job seeker
  • member of the public
  • academia / entrepreneur
  • media
...looking for ▾
  • information about VHC medicines
  • clinical data and insights on VHC medicines
  • Independent Medical Education
  • medicines in development
  • how VHC is advancing HIV treatment and care
...looking for ▾
  • information about VHC medicines
  • information and support about living with HIV
  • how to report a side effect
  • news and stories from ViiV Healthcare
...looking for ▾
  • funding / grants
  • ViiV Healthcare's approach to partnerships
  • how ViiV Healthcare works with NGOs
  • news and stories from ViiV Healthcare
  • connect with ViiV Healthcare's community
...looking for ▾
  • job opportunities
  • information about ViiV Healthcare
  • ViiV Healthcare's office locations
  • news and stories from ViiV Healthcare
...looking for ▾
  • who are ViiV Healthcare
  • corporate ethics & compliance
  • news and stories from ViiV Healthcare
...looking for ▾
  • opportunities to partner with ViiV Healthcare
  • information on ViiV Healthcare's Innovation Unit
  • news and stories from ViiV Healthcare
...looking for ▾
  • press releases
  • ViiV Healthcare's Leadership
  • news and stories from ViiV Healthcare

Tivicay

Tivicay (dolutegravir) is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia as a Section 100 item for the treatment of HIV infection.

Resources

For patients:

For HCPs:

Report adverse event

If you are a patient and have experienced an unexpected event when taking one of our medications please speak to your healthcare professional as soon as possible. To lodge a report contact:

 

Medical Information

Phone: 1800 499 226

Email:  Australia.medinfo@viivhealthcare.com